Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 501 to 550 of 8145 results

  1. Diagnostics Assessment Programme

    This guidance evaluates new, innovative diagnostic technologies. It includes all types of measurements and tests that are used to evaluate a patient's

  2. Further research is recommended to determine the impact of MRI fusion biopsy systems compared with cognitive fusion biopsy on the detection of different grades of prostate cancer.

    Recommendation ID DG53/1 Question Further research is recommended to determine the impact of MRI fusion biopsy systems compared with cognitive

  3. Further data collection or research is recommended on the impact of implementing MRI fusion biopsy systems on the rate at which biopsies can be done, capacity resources and waiting times for this procedure.

    Recommendation ID DG53/2 Question Further data collection or research is recommended on the impact of implementing MRI fusion biopsy systems

  4. The committee recommends collecting further data on clinical outcomes such as time to healing, and incorrect use of compression and its associated adverse consequences when possible.

    Recommendation ID DG52/3 Question The committee recommends collecting further data on clinical outcomes such as time to healing, and incorrect

  5. The committee recommends collecting further data on the impact of the automated devices on time to treatment for people with leg ulcers to reduce uncertainty in the economic modelling.

    Recommendation ID DG52/2 Question The committee recommends collecting further data on the impact of the automated devices on time to treatment

  6. The committee recommends more research on diagnostic accuracy in people with leg ulcers. The following considerations should be made when doing this research:

    Recommendation ID DG52/1 Question The committee recommends more research on diagnostic accuracy in people with leg ulcers. The following

  7. Helping to prevent infection

    Help for care home managers and staff to prevent infection

  8. Cookies

    How NICE uses cookies and how you can manage them.

  9. Alcohol-use disorders: diagnosis and management (QS11)

    This quality standard covers identifying and supporting adults and young people (aged 10 and over) who may have an alcohol-use disorder and caring for people with alcohol-related health problems, as well as support for their families and carers. It describes high-quality care in priority areas for improvement.

  10. AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images (DG55)

    Evidence-based recommendations on AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images

  11. NICE recommends extending use of tests for colorectal cancer which could reduce waiting time for colonoscopies

    Doctors have been advised to offer people with signs or symptoms of colorectal cancer a home test to reduce the waiting times for a colonoscopy, NICE has said in draft guidance.

  12. Irreversible electroporation for treating prostate cancer (IPG768)

    Evidence-based recommendations on irreversible electroporation for treating prostate cancer. This involves using electrical pulses to destroy the cancer cells.

  13. Rimegepant for preventing migraine (TA906)

    Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.

  14. Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (TA908)

    Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy in adults.

  15. NHS at 75

    Dr Sam Roberts, chief executive of NICE, celebrates the NHS on its 75th anniversary. She discusses how NICE has supported the NHS with its recent achievements. She also highlights how NICE is evolving; through driving value-based healthcare to support the NHS as it adapts to meet current challenges.

  16. Knowledge transfer seminars

    Learn from NICE International, part of the UK’s National Institute for Health and Care Excellence, about how to improve your nation’s health and wellbeing

  17. Speaking engagements

    Ask an expert from NICE International, part of the UK’s National Institute for Health and Care Excellence, to speak at a healthcare event in your country

  18. Oesophago-gastric cancer: assessment and management in adults (NG83)

    This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.

  19. Data collection agreement

    This agreement relates to treating cystic fibrosis patients with: Ivacaftor, tezacaftor and elexacaftor (Kaftrio®) in combination with ivacaftor for

  20. Position statement on use of the EQ-5D-5L value set for England (updated October 2019)

    Our position on use of the EQ-5D-5L valuation set for England

  21. How we develop medical technologies guidance

    It takes 38 weeks to develop a piece of medical technologies guidance. Timings are approximate and may change for some topics. The Medical...

  22. Depression in adults (QS8)

    This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.

  23. Single technology appraisal (STA) timeline

    A step-by-step timeline of the process we used to develop single technology appraisals (STA)

  24. Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention (IPG766)

    Evidence-based recommendations on botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. This involves injecting botulinum toxin type A into the urethral sphincter.

  25. Radiofrequency denervation for osteoarthritic knee pain (IPG767)

    Evidence-based recommendations on radiofrequency denervation for osteoarthritic knee pain. This involves applying heat (radiofrequency) energy to damage the nerves (denervation) that are causing pain in the knee.

  26. NICE impact diagnostic pathology

    Find out more about the progress made in implementing NICE guidance on diagnostic pathology

  27. Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)

    Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.

  28. More evidence needed to recommend Type 2 diabetes treatment tirzepatide

    More evidence is needed on the clinical and cost-effectiveness of a new treatment option for people with type 2 diabetes before it could be recommended for NHS use, a NICE committee has said.

  29. NICE launches public consultation on updates to health technology evaluations manual

    A public consultation on updates to NICE's health technology evaluations manual is now open.

  30. New health technologies need new approaches

    Dr Sam Roberts has been outlining the changes underway at NICE to meet the challenges of a rapidly evolving health technology sector and patient expectations

  31. Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option (IPG764)

    Evidence-based recommendations on endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option. This involves inserting a stent through an endoscope into the gallbladder.

  32. Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people (IPG765)

    Evidence-based recommendations on minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people. This involves inserting a rod along the spine through a small cut in the back.

  33. NICE and the public

    With your help, we're improving outcomes for people who use the NHS and other public health and social care services. Find out how you can get...

  34. Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

    Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

  35. Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)

    Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.

  36. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

    Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.

  37. Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)

    Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.

  38. Public involvement - putting you at the heart of our work

    Your experiences are vital to the development of our guidance, standards and advice. We're committed to involving people who use services, carers and

  39. Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)

    NICE is unable to make a recommendation on cemiplimab (Libtayo) for treating recurrent or metastatic cervical cancer in adults because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA901

  40. Who can register as a stakeholder?

    Find out more about the types of organisations that can register to be a stakeholder at NICE.

  41. MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery (MIB323)

    NICE has developed a medtech innovation briefing (MIB) on MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery .

  42. Tackling health inequalities in children and young people

    We've updated our health inequalities web resource so that it maps NICE guidance to frameworks for children and young people. Dr Clare Morgan, director of implementation and partnerships explains how you can use the resource to ensure you're delivering effective care.

  43. Smoking: smoking status of people with bipolar, schizophrenia and other psychoses (IND154)

    This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM124

  44. Decision aid to guide healthcare professional-patient discussions on sleeping pill prescriptions published

    Patient decision aid on medicines associated with dependence or withdrawal symptoms published

  45. Management of inflammatory arthritis

    All forms of inflammatory arthritis have similar management strategies coordinated through a multidisciplinary team. Pharmacological treatments are...

  46. NICE impact arthritis

    Why focus on arthritis? Arthritis is an umbrella term encompassing conditions in which there is pain, swelling and stiffness in the joints. Since 2001

  47. Osteoarthritis

    Osteoarthritis refers to a condition where there is joint pain accompanied by functional limitation and reduced quality of life. It mainly affects...

  48. MTA process timeline

    These are the main stages in the multiple technology appraisal process used before April 2018. It applies to evaluations that started before 1...

  49. Medicines associated with dependence or withdrawal symptoms. Patient decision aid summary version on should I stop my benzodiazepine or z-drug?

    Should I stop my benzodiazepine or z-drug? Patient decision aid: summary Do not stop taking your benzodiazepine or z-drug suddenly What are...